Kamada says CYTOGAM study links CMV immunoglobulin prophylaxis to improved outcomes in high-risk lung transplant patients

• Kamada highlighted investigator-initiated data suggesting CYTOGAM prophylaxis in high-risk lung transplants was linked to better outcomes versus no CMVIG.
• Retrospective analysis showed worse clinical outcomes without CMVIG; paired blood-cell work indicated lower innate immune activation with CMVIG prophylaxis.
• Non-clinical in-vivo model found CMVIG blunted acute lung injury and improved mortality, supporting a potential immune-modulating mechanism.
• Management expects the post-marketing program to support increased CYTOGAM utilization; full study results are expected to be published later this year.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Kamada Ltd. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202607130700PRIMZONEFULLFEED9760836) on July 13, 2026, and is solely responsible for the information contained therein.